Compare
LeonaBio, Inc. vs aTYR PHARMA INC vs Quince Therapeutics, Inc. vs Aligos Therapeutics, Inc.
| Latest fiscal year | LeonaBio, Inc. LONA | aTYR PHARMA INC ATYR | Quince Therapeutics, Inc. QNCX | Aligos Therapeutics, Inc. ALGS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $190.0K | n/a | $2.19M |
| Revenue growth (YoY) | n/a | -19.1% | n/a | -39.5% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/m | n/a | n/m |
| Net margin | n/a | n/m | n/a | n/m |
| Net income | -$105.61M | -$74.12M | -$83.98M | -$24.19M |
| EPS (Diluted) | -$24.70 | -$0.80 | -$1.68 | -$2.45 |
| Operating cash flow | -$45.73M | -$61.99M | -$41.42M | -$82.50M |
| Free cash flow | n/a | -$62.06M | -$41.78M | n/a |
| Cash & equivalents | $69.28M | $10.74M | $5.81M | $18.30M |
| Total assets | $92.15M | $93.00M | $93.52M | $88.53M |
| Total liabilities | $64.36M | n/a | $129.24M | $34.99M |
| Shareholders' equity | $27.79M | $67.48M | -$35.71M | $53.55M |
| Return on year-end equity | -380.0% | -109.8% | n/a | -45.2% |
| Shares outstanding | 9.34M | 98.03M | 55.73M | 6.18M |
Revenue, most recent five fiscal years
| Fiscal year | LeonaBio, Inc. | aTYR PHARMA INC | Quince Therapeutics, Inc. | Aligos Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $190.0K Ended 2025-12-31 | n/a | $2.19M Ended 2025-12-31 |
| 1 year earlier | n/a | $235.0K Ended 2024-12-31 | n/a | $3.61M Ended 2024-12-31 |
| 2 years earlier | n/a | $353.0K Ended 2023-12-31 | n/a | $6.19M Ended 2023-12-31 |
| 3 years earlier | n/a | $10.39M Ended 2022-12-31 | n/a | $0 Ended 2022-12-31 |
| 4 years earlier | n/a | $0 Ended 2021-12-31 | n/a | $0 Ended 2021-12-31 |